[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 275,088,992
  • Shares Outstanding, K 2,469,824
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 12,969 M
  • EBITDA $ 18,807 M
  • 60-Month Beta 0.18
  • Price/Sales 4.27
  • Price/Cash Flow 9.83
  • Price/Book 6.04

Options Overview Details

View History
  • Implied Volatility 29.36% (+1.64%)
  • Historical Volatility 25.52%
  • IV Percentile 48%
  • IV Rank 41.29%
  • IV High 40.30% on 05/15/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 5) 2.71 (2.43%)
  • Put/Call Vol Ratio 1.78
  • Today's Volume 18,619
  • Volume Avg (30-Day) 23,987
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 530,545
  • Open Int (30-Day) 495,196
  • Expected Range 108.67 to 114.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.66
  • Number of Estimates 5
  • High Estimate $2.18
  • Low Estimate $-0.20
  • Prior Year $2.13
  • Growth Rate Est. (year over year) -22.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.90 +3.23%
on 04/29/26
124.00 -10.18%
on 04/09/26
-11.80 (-9.58%)
since 04/08/26
3-Month
107.90 +3.23%
on 04/29/26
125.14 -11.00%
on 02/25/26
-10.55 (-8.65%)
since 02/06/26
52-Week
73.31 +51.93%
on 05/15/25
125.14 -11.00%
on 02/25/26
+33.73 (+43.44%)
since 05/08/25

Most Recent Stories

More News
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

Publication in Science magazine outlines blueprint for the scalable synthesis of complex orally available macrocyclic peptides Enlicitide, a...

MRK : 111.38 (-0.82%)
The Top 5 Analyst Questions From Merck’s Q1 Earnings Call

The Top 5 Analyst Questions From Merck’s Q1 Earnings Call

MRK : 111.38 (-0.82%)
Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

Salesforce (NYSE: CRM), the world’s #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), today announced...

MRK : 111.38 (-0.82%)
CRM : 181.82 (-2.43%)
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck’s oncology pipeline

MRK : 111.38 (-0.82%)
TERN : 52.95 (+0.04%)
Do Wall Street Analysts Like Merck & Co. Stock?

Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 143.49 (-0.85%)
$SPX : 7,398.93 (+0.84%)
MRK : 111.38 (-0.82%)
TERN : 52.95 (+0.04%)
Dear Veeva Systems Stock Fans, Mark Your Calendar for May 7

Veeva Systems stock pops following S&P 500 inclusion announcement.

$SPX : 7,398.93 (+0.84%)
MRK : 111.38 (-0.82%)
VEEV : 166.34 (-1.14%)
LLY : 948.45 (-2.72%)
DVN : 45.61 (+0.66%)
CTRA : 32.56 (-8.62%)
MRK Q1 Deep Dive: Oncology Strength, New Launches, and Pipeline Milestones Define Quarter

MRK Q1 Deep Dive: Oncology Strength, New Launches, and Pipeline Milestones Define Quarter

MRK : 111.38 (-0.82%)
Merck (NYSE:MRK) Surprises With Q1 CY2026 Sales

Merck (NYSE:MRK) Surprises With Q1 CY2026 Sales

MRK : 111.38 (-0.82%)
Merck: Q1 Earnings Snapshot

Merck: Q1 Earnings Snapshot

MRK : 111.38 (-0.82%)
Stocks Rise Before the Open as Investors Weigh Big Tech Earnings, Iran War News

June S&P 500 E-Mini futures (ESM26) are up +0.15%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.22% this morning as investors digest earnings reports from big U.S. tech companies and the latest...

TER : 359.77 (+1.60%)
GOOGL : 400.80 (+0.71%)
META : 609.63 (-1.16%)
AAPL : 293.32 (+2.05%)
SNDK : 1,562.34 (+16.60%)
BNP.FP : 91.550 (-1.81%)
NXPI : 294.75 (+1.56%)
MRK : 111.38 (-0.82%)
GLE.FP : 69.180 (-0.65%)
ESM26 : 7,419.00s (+0.76%)
MSFT : 415.12 (-1.34%)
UMG.A.DX : 19.780 (+1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 114.36
2nd Resistance Point 113.69
1st Resistance Point 112.53
Last Price 111.38
1st Support Level 110.70
2nd Support Level 110.03
3rd Support Level 108.87

See More

52-Week High 125.14
Last Price 111.38
Fibonacci 61.8% 105.34
Fibonacci 50% 99.22
Fibonacci 38.2% 93.11
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.